Fresenius Medical obtains exclusive global rights to commercialize Humacyl

Fresenius Medical Care and Humacyte, Inc. entered into a strategic, global partnership and a USD 150 million equity investment. This agreement has the potential to make Humacyte’s investigational human acellular vessel, Humacyl, available to more patients worldwide following approval of the product. Humacyl is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula. Under the terms of the agreement, Fresenius Medical Care will obtain the exclusive global rights to commercialize HUMACYL.

Fresenius Medical Care will be responsible for the marketing, sales and distribution of Humacyl following approval by the relevant health authorities. In addition, Fresenius Medical Care will make a USD 150 million equity investment in Humacyte to gain a 19 percent fully diluted ownership stake in the company. With the investment, Fresenius Medical Care will have the opportunity to bring transformative clinical innovation in the form of Humacyte’s bioengineered human acellular vessels to the worldwide end stage renal disease (ESRD) patient population following product approval.

“By partnering with Humacyte, Fresenius Medical Care has an opportunity to offer a dialysis vascular access option with the potential for significant clinical efficacy and safety improvements, including the potential to minimize catheter contact time to the benefit of our patients.”

Franklin Maddux
Chief Medical Officer,
Fresenius Medical Care North America